Drug Trial Radar · NCT00322907
Cotrifazid Safety and Efficacy Against Malaria
Last checked: Nov 20, 2026Latest source record: May 8, 2006 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
330
Actual
Start
Apr 2000
Primary completion
Not stated
Study completion Jan 2003
Sponsor
- Lead sponsor
- Center for Primary Care and Public Health (Unisante), University of Lausanne, SwitzerlandAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Papua New Guinea Institute of Medical Research; Swiss Tropical & Public Health Institute
- First posted
- May 8, 2006
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 6 months
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study was to assess the safety and efficacy of Cotrifazid to treat uncomplicated resistant malaria and to compare the outcome with mefloquine or quinine+sulfadoxine/pyrimethamine (SP)
Conditions
- Clinical Malaria
Interventions
Cotrifazid vs mefloquine or quinine+SPDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Clinical treatment failure rate on day 14.
- Incidence of adverse events.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Health centers
Madang and Maprik, Madang and East Sepik Province, Papua New Guinea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.